3 annual review on head & neck cancers · severe k reacti on≥ 3): in errupt tmen , resum reac...

For registration visitwww.yearinreview.in/airhnc

Academic Partners

3rd Annual Review onHead & Neck Cancers

Organized by

• Dr. B. K. Smruti • Dr. Mehul Bhansali• Dr. Kumar Prabhash

Organizing Chairpersons

• Dr. Mandar Deshpande• Dr. Sewanti Limaye• Dr. Kaustav Talapatra• Dr. Vanita Noronha

Organizing Secretaries

Password: arhncMeeting ID: 817 5175 9034

Daily Quiz for Students

13th, 19th, 20th & 21st June, 2020

WEBINAR ONLIVE Zoom

SCIENTIFIC PROGRAM

4.30 pm - 8.30 pm

Academic Partners

Dear Doctor,

On behalf of the organizing committee and Mumbai Oncology Association, we are pleased to invite you to the "3rd Annual Review on Head and Neck Cancers Conference". The will be a virtual conference and will be held through online webinar on 13-19-20-21 June 2020 (4 Hours a day).

This 3rd Annual Review on Head and Neck Cancers Conference 2020 will provide practitioners an update in head and neck cancers with a comprehensive overview of the current standard of care practices as well as review of evolving and innovative treatment approaches.

"The focus of this conference will be on latest in multidisciplinary approach to head and neck treatment, novel treatment breakthroughs and leading research publications and current best practices in supportive and survivorship care."

We will also cover important publications on cutaneous cancers, endocrine malignancies and skull-based cancers. Pertinent reconstructive and rehabilitative issues will similarly be addressed during specific sessions. Open interaction between faculty and participants will be encouraged throughout the sessions with particular emphasis during the scheduled "Tumor Board" sessions and Q & A periods.

This 3rd ARHNC conference have daily quiz for students with attractive prizes.

Looking forward to your participation.

Organized by

Regards,

Organizing ChairpersonsDr. B. K. Smruti Dr. Mehul Bhansali Dr. Kumar Prabhash

Organizing SecretariesDr. Mandar DeshpandeDr. Sewanti LimayeDr. Kaustav TalapatraDr. Vanita Noronha

Academic Partners Organized by

Patrons

• Dr. Deepak Parikh • Dr. Pankaj Chaturvedi • Dr. R. C. Mistry

Scientific Advisory Committee

• Dr. Alok Thakar • Dr. Arnab Gupta • Dr. Ashok D. Dhoble

• Dr. Avinash Pandey

• Dr. Hemant Malhotra • Dr. Monali Swain

• Dr. Poonam Joshi • Dr. Prathmesh Pai • Dr. Randeep Singh

• Dr. Ravindar Singh • Dr. Rohit Pai • Dr. Sandeep Goyle

• Dr. Sarbani Laskar • Dr. Sharad Desai

• Dr. Vikram D. Kekatpure

• Dr. Shivakumar Thiagarajan

• Dr. Vijay Patil • Dr. Yogesh Dabholkar

• Dr. Arun Balaji

• Dr. Neha Mittal

• Dr. Abhishek Mahajan• Dr. Ajay Doiphode

Academic Coordinators

• Dr. Abhishek Vaidya • Dr. Akhil Kapoor • Dr. Amit Kumar

• Dr. Apurva Garg

• Dr. Rakesh Katna • Dr. Shilpi Sharma • Dr. Trinanjan Basu

• Dr. Nikhil Kalyani • Dr. Rohit Malde • Dr. Eapen Thomas

• Dr. Pritanjali Singh• Dr. Mitali Dandekar

Merck

For

the

use

of a

Reg

iste

red

Med

ical

Pra

ctitio

ner

or a

Hos

pita

l or

a L

abor

ator

y O

nly.

IN

D/E

RB/0

320/

0056

EXP

03/2

2SCHEDULE H PRESCRIPTION DRUG – CAUTION Not to be sold by retail without the prescription of a Registered Medical PractitionerWarning: To be sold by retail on the prescription of a Oncologist onlyBefore prescribing ERBITUX, please consult full prescribing information. Presentation: *ERBITUX 5 mg/mL solution for infusion. Excipients: sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide, water for injections. Indications : Epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer (mCRC): in combination with irinotecan-based chemotherapy (CT), or in first-line in combination with FOLFOX, or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. Squamous cell carcinoma of the head and neck (SCCHN): in combination with radiation therapy (RT) for locally advanced (LA) disease or with platinum-based chemotherapy (pt-CT) for recurrent and/or metastatic (R/M) disease. Dosage and administration: Once a week, intravenously with an infusion pump, gravity drip or a syringe pump; separate infusion line. Initial dose 400 mg/m2 (should be given slowly with max. infusion rate: 5 mg/min; the recommended infusion period is over 120 mins); subsequent weekly doses 250 mg/m2 (Max. infusion rate: 10 mg/min; recommended over 60 mins). Supervision/monitoring by a physician experienced in antineoplastic therapy throughout infusion and for at least one hour afterwards is required. Resuscitation equipment must be ensured. Prior to first infusion: premedication with antihistamines and corticosteroids at least 1 hour prior to administration of ERBITUX; also recommended for all subsequent infusions. Administer CT not earlier than one hour after ERBITUX infusion. mCRC: administer ERBITUX until disease progression. Wild-type RAS tumor status must be verified prior to first infusion by an experienced laboratory using validated test methods. LA SCCHN: start ERBITUX therapy one week before RT and continue throughout treatment. R/M SCCHN: administer ERBITUX in combination with pt-CT and continue until disease progression. Special Populations: Elderly: no dose adjustment required (limited experience in patients ≥75 years). Pediatric patients (<18 years): efficacy not established, no new safety signals. Others: only patients with adequate renal, hepatic and hematological parameters have been investigated. Contraindications: Known severe hypersensitivity reactions (grade 3/4 NCI CTCAE). In combination with oxaliplatin-containing CT if mutated/unknown RAS status. Contraindications for concomitantly used CT or RT must be considered. Special warnings and precautions: Severe infusion-related reactions (IRRs) including anaphylactic reactions: May commonly occur, in some cases with fatal outcome; immediate and permanent discontinuation of ERBITUX therapy; may necessitate emergency treatment. May be anaphylactic or anaphylactoid in nature or represent a cytokine release syndrome. Symptoms may occur during the first infusion and for up to several hours afterwards or with subsequent infusions and may include bronchospasm, urticaria, increase or decrease in blood pressure, loss of consciousness or shock. In rare cases, angina pectoris, myocardial infarction or cardiac arrest have been observed. The risk for anaphylactic reactions is much increased in patients with a history of allergy to red meat or tick bites or positive results of tests for IgE antibodies against Erbitux. Mild/moderate IRRs: decrease infusion rate, also for all subsequent infusions. Closely monitor patients with reduced performance status (PS) and pre-existing cardio-pulmonary disease. Skin reactions: oral tetracyclines and topical 1% hydrocortisone cream with moisturizer may be considered for prophylactic use and medium to high-potency topical corticosteroids or oral tetracyclines for treatment (acc. to clinical practice guidelines). Severe skin reaction (≥grade 3): interrupt treatment, only resume if reaction resolves to grade 2. Second or third occurrence of severe skin reactions: resume at lower dose (200 mg/m2 after second, 150 mg/m2 after third) only if reaction resolves to grade 2. Fourth occurrence or failure to resolve to grade 2 during interruption: permanent discontinuation. Interstitial lung disease: if diagnosed, discontinuation and appropriate treatment. Electrolyte disturbances: determination of serum electrolyte levels recommended prior to and periodically during treatment. Electrolyte repletion (e.g. hypomagnesaemia; hypokalaemia as a consequence of diarrhea; hypocalcemia, particularly in combination with pt-CT) is recommended. Neutropenia and related infectious complications: careful monitoring is recommended particularly in patients experiencing skin lesions, mucositis or diarrhea that may facilitate the occurrence of infections. Severe and sometimes fatal cardiovascular events: increased frequency associated with age ≥ 65 years or PS has been observed. Patient cardiovascular status, PS and concomitant administration of cardiotoxic compounds (e.g. fluoropyrimidines) should be taken into account. Acute or worsening symptoms of keratitis: refer promptly to an ophthalmologist, consider benefit/risk of continuing use. Confirmed ulcerative keratitis: interruption or discontinuation of ERBITUX. Use with caution in patients with history of keratitis, ulcerative keratitis or severe dry eye (e.g. use of contact lenses). CRC patients with mutated/unknown RAS status: ERBITUX should not be used since negative effects on PFS and OS as add-on to FOLFOX4 have been reported in RAS mutated tumors. There is limited experience in combination with RT in mCRC. Fertility, pregnancy and lactation: Only use during pregnancy or in women with inadequate contraception if potential benefits justify potential risks to fetus. Breast-feeding during treatment and 2 months later is not recommended. Effects on male/female fertility have not been evaluated. Undesirable effects: Very common (≥1/10): skin reactions (e.g. acne-like rash and/or pruritus, dry skin, desquamation, hypertrichosis, or nail disorders, single cases of skin necrosis), hypomagnesaemia, mild/moderate IRRs (e.g. fever, chills, dizziness, dyspnea), increased liver enzyme levels and mucositis, in some cases severe. Mucositis may lead to epistaxis. Common (≥1/100, <1/10): headache, conjunctivitis, diarrhea, nausea, vomiting, fatigue, dehydration, hypocalcemia, anorexia, weight loss, severe IRRs. Uncommon (≥1/1000, <1/100): blepharitis, keratitis, deep vein thrombosis, pulmonary embolism or interstitial lung disease. Very rare (<1/10,000): Stevens-Johnson syndrome/toxic epidermal necrolysis. Frequency not known: superinfection of skin lesions with subsequent complications (e.g. cellulitis, erysipelas, staphylococcal scalded skin syndrome, necrotising fasciitis, sepsis), aseptic meningitis. In combination with local RT in SCCHN: typical undesirable effects of RT (e.g. mucositis, radiation dermatitis, dysphagia or leukopenia, mainly as lymphocytopenia). In combination with ERBITUX: slightly higher rates of severe acute radiation dermatitis, mucositis and late RT-related events. Interactions: Fluoropyrimidines: increased frequency of hand-foot syndrome and cardiac ischaemia (e.g. myocardial infarction and congestive heart failure). Capecitabine and oxaliplatin (XELOX): frequency of severe diarrhoea may be increased. pt-CT: increased frequency of severe leukopenia/neutropenia, which may lead to a higher rate of febrile neutropenia, pneumonia and sepsis. Storage: Store in a refrigerator (2ºC – 8ºC) Shelf life: 48 months

Date of Information: June 2019 Based on CCDS of Cetuximab V.16.0 dated 28th June 2018.For further information refer to full prescribing information or write to:

Merck Specialities Pvt Ltd.,

Godrej One, 8th Floor, Pirojsha Nagar, Eastern Express Highway, Vikhroli (East) Mumbai – 400079

Erbitux (Cetuximab) Abbreviated Prescribing Information:

Our mission never stops

Right time

Right patient

Right response

1. Bonner JA et al. N Engl J Med 2006: 354: 567-568, 2. Curran et al. J Clin Oncol 25: 2191-2197, 3. Guigay J, et al. Ann Oncol 2015;26:1941–1947; 4. Bossi P, et al. Ann Oncol 2017;28:2820–2826;5. Tahara M, et al. Ann Oncol 2018;29:1004–1009; 6. Friesland S, et al. ASCO 2018 (Abstract 6032); 7. Vermorken JB, et al. N Engl J Med 2008;359:1116–1127; 8. Mesia R et al. Ann Oncol 2010:; 21:1967-1973

In Locally advanced SCCHN:• Erbitux+RT prolongs survival & maintains quality of life1,2

• Erbitux+RT helps patients to complete the therapy2

• Erbitux+CT provides consistently high mOS and ORR3-7

• Erbitux+CT improves quality of life through symptom control7,8

In 1L RM SCCHN:


Scientific Program

Day 1, Saturday, 13th June16:15 - 16:55 Student Quiz - IDA Quiz Master: Eapen Thomas, Oral and Maxillofacial Surgeon, Kerala16:55 - 17:00 Welcome Address by Mandar Deshpande Academic Coordinators: Trinanjan Basu, Radiation Oncologist, Mumbai Akhil Kapoor, Medical Oncologist, Mumbai Shilpi Sharma, Surgical Oncologist, Delhi

Chairpersons : S. K. Shrivastava, Radiation Oncologist, Mumbai Dhairyasheel Savant, Surgical Oncologist, Mumbai Ramana Reddy, Maxillofacial Surgeon, Hyderabad17:00 - 17:10 Reviewer: Ishita Gupta, Maxillofacial Surgeon, Mumbai Oral smokeless tobacco consumption pattern among rural Indian cancer patients: A prospective survey Author: Avinash Pandey Citation: South Asian J Cancer. Jan-Mar 2020;9(1):17-19 Malignant transformation risk of oral lichen planus: A systematic review and comprehensive meta-analysis Author: Miguel Ángel González-Moles Citation: Oral Oncol. 2019 Sep; 96:121-130.

17:10 - 17:20 Reviewer: Neha Mittal, Pathologist, Mumbai A proposal to revise the histopathologic grading system of early oral tongue cancer incorporating tumor budding Author: Amr Elseragy Citation: Am J Surg Pathol 2019;43:703–709

Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavityMD1 Author: Dan P. Zandberg Citation: Head & Neck. 2019;41:2514–2524

KEY PUBLICATIONS OF CANCER OF ORAL CAVITY - PART I


Scientific Program

Day 1, Saturday, 13th June17:20 - 17:30 Reviewer: Mitali Dandekar, Surgical Oncologist, Patna The significance of tumor budding in oral cancer survival and its relevance to the eighth edition of the American Joint Committee on cancer staging system Author: Yi-Yun Ho DDS Citation: Head & Neck. 2019;41:2991–3001

Pathological risk factors stratification in pN3b oral cavity squamous cell carcinoma: Focus on the number of positive nodes and extranodal extension Author: Chun-Ta Liao Citation: Oral Oncol. 2018 Nov;86:188-194

17:30 - 17:40 Reviewer: Charudatta Naik, Oral and Maxillofacial Surgeon, Mumbai Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype Author: O Iocca Citation: Head and neck, 2020

Usefulness of contrast-enhanced CT in the evaluation of depth of invasion in oral tongue squamous cell carcinoma: Comparison with MRI Author: Akira Baba Citation: Oral Radiology. 2020 Feb 21:1-9.17:40 - 17:45 Chairperons Remarks

Chairpersons : Vinod Gite, ENT & Head and Neck Surgeon, Mumbai A. Thangavelu, Oral and Maxillofacial Surgeon, Tamil Nadu Ramesh Billimagga, Radaition Oncologist, Bangalore17:45 - 18:15 Panel discussion on presented publications Moderator: Arvind Krishnamurthy, Surgical Oncologist, Chennai Panelists: Sanjay Joshi, Oral and Maxillofacial Surgeon, Mumbai Abhishek Mahajan, Radiologist, Mumbai Deepali Jain, Pathologist, Delhi Anuja Deshmukh, Surgical Oncologist, Mumbai Mandar Deshpande, Surgical Oncologist, Mumbai Mitali Dandekar, Surgical Oncologist, Patna18:15 - 18:20 Chairperons Remarks


Scientific Program

Day 1, Saturday, 13th June

Chairpersons : Rajesh Valand, ENT Surgeon, Mumbai Shekhar Kesari, Radiation Oncologist, Patna Bachi Hathiram, ENT Specialist, Mumbai18:20 - 18:30 Reviewer: Devendra Chaukar, Surgical Oncologist, Mumbai Patterns of failure and outcomes in cT4 Oral Squamous Cell Carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A matched pair analysis Author: Shivakumar Thiagarajan Citation: Oral Oncol. 2020 Jan; 100:104455.

A prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery to neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. ASCO 2020. 6518 Author: D Chaukar Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 6518-6518.

18:30 - 18:40 Reviewer: Apurva Garg, Surgical Oncologist, Kolkata Adequacy of surgical margins in oral cancer patients with respect to various types of reconstruction Author: Apurva Garg Citation: South Asian J Cancer. Jan-Mar 2020;9(1):34-37

Impact of dysplastic surgical margins for patients with oral squamous cell carcinoma Author: Tseng-Cheng Chen Citation: Oral Oncol. 2019 Oct; 97:1-6

KEY PUBLICATIONS OF CANCER OF ORAL CAVITY - PART II


Scientific Program


18:40 - 18:50 Reviewer: Pranav Chadha, Radiation Oncologist, Mumbai Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). Author: Naomi Kiyota Citation: ASCO Abstract 2020

Randomized clinical trial on 7-days-a-week postoperative radiotherapy vs. concurrent postoperative radiochemotherapy in locally advanced cancer of the oral cavity/ oropharynx Author: G. Woznia Citation: ASTRO 2019 : Abstract 109

18:50 - 18:55 Reviewer: Bhavin Visariya, Radiation Oncologist, Mumbai Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin ASCO 2020.12092 Author: Nandini Sharrel Menon Citation: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 12092-1209218:55 - 19:00 Chairperons Remarks

Chairpersons : Sharmila Agarwal, Radiation Oncologist, Mumbai Shashank Pandya, Surgical Oncologist, Ahemdabad19:00 - 19:30 Panel discussion on presented publications Moderator: Rajendra Toprani,Surgical Oncologist,Ahemdabad Panelists: Caleb Harris, Surgical Oncologist, Shillong Shivakumar Thiagarajan, Surgical Oncologist, Mumbai Smitha Saldanha, Medical Oncologist, Bangalore Mudit Agarwal, Surgical Oncologist, Delhi Sayan Paul, Radiation Oncologist, Hyderabad Rohit Malde, Radiation Oncologist, Mumbai Vikas Talreja, Medical Oncologist, Delhi

Organized byAcademic Partners

Scientific Program


19:30 - 19:35 Chairperons Remarks

19:35 - 19:55 Sponsored Talk - Intas

19:55 - 20:00 Important Announcement

20:00 - 20:30 Student Quiz - Oncology Quiz Master: Rohit Pai, Medical oncologist, Mumbai


Scientific Program

Day 2, Friday, 19th June

Quiz for dental surgery students based on abstracts presented on day 1

Key publications on oropharyngeal cancer

Key publications on laryngeal cancer

Key publications on nasopharyngeal cancer

Eisai symposium

Quiz for radiation, medical and surgical oncology students based on abstractspresented daily


Quiz for ENT and maxillofacial surgery students based on abstracts presented on day 2

Key publications on new interventions in head and neck cancers

Key publications on thyroid cancer

Key publications on cancer of salivary gland

Multidisciplinary panel discussion on managment of head and neck cancers in timeof COVID 19

Merck Serono symposium



Scientific Program

Day 4, Sunday, 21st June

Quiz for ENT and maxillofacial surgery students based on abstracts presented on Day 3

Biomarkers in head and neck cancers

Key publications on recurrent/metastatic head and neck Cancers

Key publications on supportive care in head and neck cancers

Key publications on special population in Head and Neck Cancers (Elderly/HPV/Rare)

Industry Symposium



Academic Partners

Dr. Ravindar SinghPresident

Senior Dental Surgeon,Assam

Dr. Sanjay JoshiOMF Surgeon

Hon. Joint Secretary,Mumbai

Dr. Parvesh MehraProfessor & HOD LHMC

Delhi

Dr. Ashok D. DhobleHon.Secretary GeneralSenior Dental Surgeon,

Mumbai


TreasurerProfessor, Head & Neck Surgery,

Mumbai

Dr. Gouri Pantvaidya

Academic Partners

PresidentConsultant Surgeon Head & Neck

Surgical and Professor,New Delhi

Dr. Alok ThakarSecretary

Senior Consultant-Head & NeckSurgical Oncology,

Bangalore

Dr. Vikram D. Kekatpure

Foundation for Head and Neck Oncology (FHNO)

Indian Association of Surgical Oncology (IASO)

Dr. Arnab GuptaPresident

Consultant Surgical Oncologist,Kolkata

Academic Partners

Dr. Rajendra TopraniPresident Elect

Consultant Surgical Oncologist,Delhi

Dr. Sharad DesaiSecretary

Consultant Surgical Oncologist,Sangli

Dr. P. K. DasVice President

Consultant Surgical Oncologist,Cuttack



Indian Society of Medical and Paediatric Oncology (ISMPO)

Academic Partners

Dr. Govind BabuPresident

Consultant Medical Oncologist,Bangalore

Dr. Randeep SinghJoint Secretary

Consultant Medical Oncologist,Delhi

Dr. Kumar PrabhashTreasurer

Consultant Medical Oncologist,Mumbai

Dr. B. K. SmrutiSecretary

Consultant Medical Oncologist,Mumbai


The Association of Otolaryngologists of India (Mumbai Branch)

Academic Partners

Dr. Yogesh DabholkarPresident

Consultant ENT & Head Neck Surgeon,Mumbai

Dr. Ajay DoiphodeHon. Secretary


Dr. Adip ShettyHon. Treasurer


Dr. Ritu ShethVice President


Students Quiz


RIVER ROUTE Creative Group, LLPUnit No. 9, Cama Industrial Premises Co-Op Society Ltd., Sunmil Compound,

Lower Parel (W), Mumbai - 400 013.Mobile: Nilesh Pawar: +91 9975759495/Email: [email protected]

Webinar Managed by

• Daily Quiz for students of all speciality

• Students have to register separately for daily quiz

• Registration of students participating in the quiz will be approved by their respective speciality societies

• Win Attractive Prizes Daily

• For any query related to quiz please write to [email protected]

www.yearinreview.in/airhnc

Find below registration link for the quiz

3 annual review on head & neck cancers · severe k reacti on≥ 3): in errupt tmen , resum reac...

Documents